Best Oncology Companies in Toronto, Canada
The 46 best Oncology companies in Toronto, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Geneseeq.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Toronto
| # | Company | Disclosed funding | Last round | Employees | Founder | Stage | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Geneseeq Providing personalised cancer treatment solutions based on patients genomic profile 55Talent top 28%Funding top 31%Moat top 40%Market bottom 49% All 5 signals ▾Talenttop 28% Fundingtop 31% Moattop 40% Marketbottom 49% Globalbottom 45% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $128M across 3 rounds · 3 rounds over 12 yrs (0.2/yr) rank vs industry peers · Fliar Intelligence Index 55/100 | $128M | 79 mo ago | — | Xiaonan Wang Co-Founder & CTO | Series D | — | — |
| 2 | Trillium Therapeutics Developer of therapeutics for the treatment of cancer | $102M | 71 mo ago | 33 | — | Acquired | 180 patents CD47 immune checkpoint blockade therapies and combination cancer immunotherapy agents. | — |
| 3 | Notch Therapeutics Developer of stem-cell derived immune cell therapies | $100M | 27 mo ago | 90 | Shreya Shukla Founder | Series A | 18 patents Engineered T‑cell generation from stem cells and AI‑driven cellular outcome prediction | — |
| 4 | Radiant Biotherapeutics Developer of therapeutics for cancer, auto-immune and infectious diseases 37Patents top 33%Funding top 34%Moat top 38%Innovation top 40% All 9 signals ▾Patentstop 33% Fundingtop 34% Moattop 38% Innovationtop 40% Techtop 41% Growthbottom 47% Globalbottom 40% Marketbottom 26% Newsbottom 18% Patents: 38 patents matched (strict assignee match) · 38 filings since 2022 vs 0 in 2017-21 Funding: Raised $43.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $43M | 23 mo ago | 11 | — | Series A | 38 patents Engineered multibody protein therapeutics targeting TNF receptors and multivalent cytokine modulation | — |
| 5 | 3T Biosciences Developer of T-cell-based cancer immunotherapies to fight cancer | $40M | 47 mo ago | 33 | Leah Sibener Co-Founder | Series A | 27 patents Therapeutic antibodies targeting high‑density EGFR and ErbB2 receptor overexpression | — |
| 6 | Northern Biologics Developing antibody therapeutics for cancer and fibrosis | $40M | 135 mo ago | 21 | — | Acqui-Hired | 2 patents Patents concentrated in health & consumer products | — |
| 7 | Arius Research Speciality company involved in discovery and development of antibody therapeutics for various cancer | $22M | 245 mo ago | 31 | David S Young Founder | Acquired | — | — |
| 8 | RNA Diagnostics Developer of diagnostic assays for the detection of cancer | $14M | 58 mo ago | 11 | — | Series A | 30 patents RNA disruption assays for monitoring cancer therapy response and treatment efficacy | — |
| 9 | Profound Medical Developer of image guided prostate ablation system for cancer treatment 80Patents top 25%Funding top 31%Innovation top 33%Tech top 34% All 12 signals ▾Patentstop 25% Fundingtop 31% Innovationtop 33% Techtop 34% Moattop 35% Growthtop 36% Newstop 39% Markettop 40% Fin. healthtop 41% Globaltop 44% AItop 45% Partnerstop 45% Patents: 171 patents matched (strict assignee match) · 60 filings since 2022 vs 85 in 2017-21 Funding: Raised $12.9M across 11 rounds · 11 rounds over 18 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $13M | 8 mo ago | 131 | — | Public | 171 patents Image-guided thermal therapy systems and advanced ultrasound probe hardware for medical interventions | — |
| 10 | Miikana Therapeutics Developer of small molecules to treat various cancer | $7M | 266 mo ago | — | Dinesh Patel Co-Founder & CEO | Series A | — | — |
| 11 | Pattern Pharma Developer of immunotherapies to treat cancers and infectious diseases | $7M | 16 mo ago | 5 | — | Series A | — | — |
| 12 | Medifocus Developer of microwave generated heat therapy for Breast cancer and BPH | $6M | 144 mo ago | 9 | — | Late Stage | — | — |
| 13 | Xillix Technologies Real-time fluorescence imaging system | $6M | 247 mo ago | 7 | — | Deadpooled | 17 patents Fluorescence and reflectance endoscopic imaging systems for medical diagnostics | — |
| 14 | Telo Genomics Developer of non-invasive prognostic and diagnostic applications that improve disease treatment 37Moat top 31%News top 38%Talent top 39%Partners top 40% All 11 signals ▾Moattop 31% Newstop 38% Talenttop 39% Partnerstop 40% Patentstop 43% Fundingtop 44% AItop 45% Growthtop 48% Innovationbottom 48% Globalbottom 33% Marketbottom 24% Moat: Editorial + unicorn rating 6/10 · IP moat: 9 patents News: 9 BI events in 12 mo (of 37 tracked, 6 types) · -25% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 5 mo ago | 6 | Sherif Louis CEO | Public | 9 patents Genomic diagnostic assays for detecting and monitoring smoldering multiple myeloma | — |
| 15 | Proteocyte Provider of diagnostic test to predict risk of developing cancers | $2M | 15 mo ago | 5 | — | Series A | — | 2 launchs |
| 16 | KalGene Pharmaceuticals Developing therapeutics and companion diagnostics for Cancer and Alzheimer's. | $2M | 55 mo ago | 2 | — | Series A | — | — |
| 17 | IntelliStem Developer of cell therapy medicine for cancer patient | $1M | 50 mo ago | — | Riam Shammaa Founder & CEO | Seed | — | — |
| 18 | Focal Healthcare Guidance system for prostate biopsy | $870K | 119 mo ago | — | Chicuong La Founder and CEO | Seed | 8 patents Mechanical interfaces and counterbalance systems for medical imaging patient positioning | 1 partnership |
| 19 | Sairiyo Therapeutics Developer of therapeutic solutions for the treatment of rare diseases | $300K | 37 mo ago | — | Paul Slyke Co-Founder & CSO | Acqui-Hired | — | — |
Top 12 Oncology companies in Toronto
#1
Public · Toronto, Ontario · founded 2008 · 131 employees$12.9Mraised▾
Developer of image guided prostate ablation system for cancer treatment. The company uses proprietary technology and provide TULSA-PRO is an AI-powered, MRI-guided, incision-free robotic ablation system for the ablation of prostate tissue.
- Dec 2025Post IPO$6.5M
- Jan 2024Post IPO—
- Jul 2020Post IPO$46M
- Mar 2018Post IPO$34.5M
#2
Public · Toronto, Ontario · founded 2011 · 6 employees$5.5Mraised▾
Developer of non-invasive prognostic and diagnostic applications that improve disease treatment. The company has a proprietary technology that uses a quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease-associated genetic instability. It is developing Telo-MM application to provide e information to medical professionals in the treatment of Multiple Myeloma.
- Mar 2026Post IPO—
- Dec 2024Post IPO$1.8M
- May 2023Post IPO$2M
- Jul 2021Post IPO$1.7M
#3
Series A · Toronto, Ontario · founded 2020 · 11 employees$43Mraised▾
Developer of therapeutics for cancer, auto-immune and infectious diseases. It offers multi-valent, multi-specific antibody therapeutics based on antibody engineering platform that targets biological pathways to treat diverse diseases.
- Sep 2024Series A$35M
- Apr 2023Seed$8M
#4
Series A · Toronto, Ontario · founded 2018 · 5 employees$6.9Mraised▾
Pattern Pharma is developing immunotherapies to treat cancers and infectious diseases. Its lead candidate, PAR-1 modulates the innate immune system (dendritic cells, macrophages, and NK cells). The candidate is PRR (Pattern Recognition Receptor) TLR-4 agonist and is being tested a stand-alone product and in combination therapy.
- Apr 2025Series A$798.5K
- Feb 2024Series A$275K
- May 2021Series A$4.1M
- May 2021Seed$1.6M
#5
Series A · Toronto, Ontario · founded 2018 · 90 employees$100.5Mraised▾
Developer of stem-cell-derived immune cell therapies. The proprietary Engineered Thymic Niche (ETN) platform enables the expansion and differentiation of induced pluripotent stem cells (iPSCs) are fully defined, feeder-free, and serum-free cultures into mature T cells and other types of immune cells.
- May 2024Series A$15.5M
- Feb 2021Series A$85M
#6
Series A · Toronto, Ontario · founded 2011 · 5 employees$1.6Mraised▾
Provider of diagnostic test to predict risk of developing cancers. The company's flagship product Straticyte uses antibodies for detecting clinically validated biomarkers that have been associated with oral cancers on biopsies of lesions. It uses a proprietary algorithm to analyze the distribution of these biomarkers and classifies patients into high risk or low risk for the development of oral cancer.
- May 2025Series A$21.7K
- Nov 2024Series A$4.1M
- Dec 2023Seed$36.9K
- Jul 2023Seed$37.9K
#7
Acquired · Toronto, Ontario · founded 1996 · 33 employees$101.9Mraised▾
Developer of therapeutics for the treatment of cancer. Its lead programs, SIRPaFc, and a CD200 monoclonal antibody (mAb), target two key immunoregulatory pathways that tumor cells exploit to evade the host immune system. SIRPaFc which is entering phase I study is an antibody-like fusion protein that blocks the activity of CD47, a molecule that is upregulated on tumor cells in acute myeloid leukemia (AML) and numerous other malignancies. The CD200 mAb is a fully human monoclonal antibody that blocks the activity of CD200, an immunosuppressive molecule that is overexpressed by many hematopoietic and solid tumors. Its other clinical-stage programs include tigecycline which is being evaluated in a multi-center Phase I study in patients with AML and TTI-1612, which has been tested in a 28-patient Phase I trial in interstitial cystitis (IC) patients.
- Sep 2020Post IPO$25M
- Dec 2017Post IPO$20M
- 2017Post IPO—
- Jan 2014Post IPO$25.6M
#8
Series D · Toronto, Ontario · founded 2012$128.4Mraised▾
Geneseeq is a health solutions company that specializes in personalized cancer care and provides treatment solutions based on the comprehensive analyses of patients’ genomic profile (RNA) using NGS techniques primarily has developed customized RNA extraction protocols for all kinds of patient sample materials, including surgical sections, core needle biopsies, FFPE samples, and ultra-low input samples.
- Dec 2019Series D$114.4M
- Jul 2017Series C—
- Jun 2016Series B$9.4M
- Aug 2014Series A$4.7M
#9
Series A · Toronto, Ontario · founded 2017 · 33 employees$40Mraised▾
Developer of T-cell-based cancer immunotherapies to fight cancer. It offers therapeutics based on synthetic biology and machine learning to cure solid cancers and autoimmune diseases.
- Aug 2022Series A$40M
- Oct 2017Seed—
- Sep 2017Seed—
#10
Series A · Toronto, Ontario · founded 2010 · 11 employees$13.8Mraised▾
Developer of diagnostic assays for the detection of cancer. The flagship product RNA Disruption Assay (RDA) measures cancer response to chemotherapy by assessing the level of rRNA disruption in biopsy samples. Its therapeutic application is for the detection of breast cancer.
- Sep 2021Series A$8M
- Nov 2018Series A$5M
- Sep 2015Angel$800K
#11
Acqui-Hired · Toronto, Ontario · founded 2014 · 21 employees$40Mraised▾
Northern Biologics develops a portfolio of antibody-based therapeutics for oncology and fibrosis. The company has acquired the MSC-1 (phase I trials) antibody for targeting immunosuppressive cytokine in the tumor microenvironment called leukemia inhibitory factor (LIF). The company's therapeutic antibody candidates are designed to target the effector proteins in cancer pathways such as Wnt signaling pathway. The company has a strategic collaboration with Celgene Corporation.
- Apr 2015Series B$30M
- Dec 2014Series A$10M
#12
Acquired · Toronto, Ontario · founded 1999 · 31 employees$21.5Mraised▾
Arius Research is a biotechnology company, engages in the discovery and development of antibody therapeutics primarily focusing on breast, prostate, ovarian, colorectal, pancreatic and lung cancers, leukemia, and melanoma. It identifies monoclonal antibodies targeting various cancer indications through its technology platform functionfirst. Product pipeline includes CD63 program that is in preclinical studies for various cancer indications; ARH460-16-2, an antibody targeting the cancer stem cell antigen CD44; AR36A36.11.1 and AR10A304.7, which targets the complement-inhibitory molecule CD59; AR47A6.4.2 and AR52A301.5, which are monoclonal antibodies directed to the cancer-associated protein TROP-2 that is homologous to human EpCAM, an another cell surface cancer related protein; and AR40A746.2.3 that targets leukemia cancer stem cells. It also has antibody programs targeting the MCSP antigen and 37LRP. It has partnerships with Oxford BioMedica plc, Xerion Pharmaceuticals AG, PDL BioPharma, Medarex, Genentech, and Takeda Pharmaceutical Company Limited.
- Mar 2006PE$21.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology in Toronto is moving
A read on the academic research around Oncology in Toronto — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 128 papers.
- University of Toronto121
- Toronto General Hospital3
- Toronto Metropolitan University3
- Toronto Western Hospital2
- Toronto Rehabilitation Institute2
- Tumor microenvironment3→20
- Cancer research2→11
- Tumor microenvironment1→29
- Cancer research2→16
- Stromal cell1→3
- Cancer1→7
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.